CERTOLIZUMAB PEGOL IN THE TREATMENT OF TAKAYASU ARTERITIS: THE FIRST EXPERIENCE AND PROSPECTS

CERTOLIZUMAB PEGOL IN THE TREATMENT OF TAKAYASU ARTERITIS: THE FIRST EXPERIENCE AND PROSPECTS

Certolizumab pegol (CZP) is the only pegylated biological agent (BA) that does not contain an Fc fragment, which minimizes its transplacental transfer. Takayasu arteritis mostly occurs in reproductive-aged women.Objective: to evaluate the efficacy and safety of CZP used to treat standard immunosuppr...

Full description

Bibliographic Details
Main Authors: P. I. Novikov, I. O. Smitienko, M. V. Sokolova, S. V. Moiseev
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2018-07-01
Series:Научно-практическая ревматология
Subjects:
tnf-α inhibitors
takayasu arteritis
certolizumab pegol
Online Access:https://rsp.mediar-press.net/rsp/article/view/2568

Internet

https://rsp.mediar-press.net/rsp/article/view/2568

Similar Items